What type of study is this?

This is a Validation Study study.

What question did this study set out to answer?

To develop a non-invasive method using cfDNA to assess tumor proliferation risk in mantle cell lymphoma.

December 8, 2025BloodOpen Access

Non-invasive Mantle Cell Lymphoma risk stratification by inference of tumor proliferation from cfDNA

View Full Paper

Ask AI

Bookmark

Authors

JSJoseph G. Schroers‐Martin MEMohammad Shahrokh Esfahani AAAsh A. Alizadeh

Discussion

Member takes

Overview

Randomised trial demonstrates noninvasive cfDNA profiling predicts tumor proliferation in mantle cell lymphoma, suggesting improved precision medicine.

Key Points

To develop a non-invasive method using cfDNA to assess tumor proliferation risk in mantle cell lymphoma.
Profiled 161 samples from 117 patients in the Phase 3 randomized LYMA trial.
Utilized RNA-Seq for tumor specimens and EPIC-Seq for plasma specimens.
Developed a deep generative ML model (iEPIC) to infer gene expression from cfDNA fragmentomic features.
Computed MCL35 scores from predicted profiles for survival stratification.
Higher MCL35 scores correlated with worse progression-free survival (PFS) and overall survival (OS).
The iEPIC model improved noninvasive measurements' correlation with invasive tissue results by ~23%.
Achieved AUC of 0.73 for predicting early progression (POD24) status, comparable to tumor RNA-Seq results.

Cite This Study

Schroers‐Martin et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d77d https://doi.org/10.1182/blood-2025-1789

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

Non-invasive Mantle Cell Lymphoma risk stratification by inference of tumor proliferation from cfDNA

View Full Paper

Ask AI

Bookmark

Authors

JSJoseph G. Schroers‐Martin MEMohammad Shahrokh Esfahani AAAsh A. Alizadeh

Discussion

Member takes

Overview

Randomised trial demonstrates noninvasive cfDNA profiling predicts tumor proliferation in mantle cell lymphoma, suggesting improved precision medicine.

Key Points

To develop a non-invasive method using cfDNA to assess tumor proliferation risk in mantle cell lymphoma.
Profiled 161 samples from 117 patients in the Phase 3 randomized LYMA trial.
Utilized RNA-Seq for tumor specimens and EPIC-Seq for plasma specimens.
Developed a deep generative ML model (iEPIC) to infer gene expression from cfDNA fragmentomic features.
Computed MCL35 scores from predicted profiles for survival stratification.
Higher MCL35 scores correlated with worse progression-free survival (PFS) and overall survival (OS).
The iEPIC model improved noninvasive measurements' correlation with invasive tissue results by ~23%.
Achieved AUC of 0.73 for predicting early progression (POD24) status, comparable to tumor RNA-Seq results.

Cite This Study

Schroers‐Martin et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d77d https://doi.org/10.1182/blood-2025-1789

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark